查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1344278

仿製药市场：按治疗用途、给药途径和分销管道分类：2023-2032 年全球机会分析和产业预测

Generic Drugs Market By Therapeutic Application, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 252 Pages | 商品交期: 2-3个工作天内

价格

仿製药市场预计到 2022 年将达到 3,853 亿美元，到 2032 年将达到 8,357 亿美元，2023 年至 2032 年复合年增长率为 8.1%。

仿製药市场-IMG1

仿製药是指在剂型、功效、给药方法、品质、性能特征、用途等方面与原厂药相似并已获得原厂药上市许可的药品。 仿製药的价格低于品牌药。

糖尿病、癌症和心血管疾病等慢性疾病的快速成长推动了仿製药市场的成长。 根据世界癌症研究基金会 (WCRF) 的数据，2020 年全球估计有 1,810 万人患有癌症，其中包括 930 万名男性和 880 万名女性。 此外，仿製药的实惠价格以及最新产品的批准和推出也有助于市场成长。 例如，2021年2月，研究驱动型全球综合製药公司Glenmark Pharmaceuticals宣布在印度推出肾癌药物舒尼替尼口服胶囊的仿製药SUTIB。

此外，品牌药成本的上涨、对仿製药的高需求以及对仿製药的认识不断增强也促进了市场的成长。 此外，全球仿製药市场的领先公司正在采取各种策略，例如产品发布、收购和研发投资，以推动仿製药的发展，以加强其市场地位并保持竞争力。我们正在招聘。

此外，糖尿病盛行率的惊人成长、仿製药的技术进步以及老年人口的增加是推动市场成长的一些主要因素。 老年人更容易患糖尿病和高血压等慢性疾病。 然而，对仿製药一致性和稳定性的担忧正在阻碍市场成长。 相反，人们对仿製药的认识不断增强，预计将在不久的将来为市场成长提供有利的机会。 此外，仿製药领域的广泛研发活动以及医疗保健基础设施的显着改善预计将为预测期内的市场扩张开闢新途径。

目录

第1章简介

第 2 章执行摘要

第3章市场概述

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 慢性疾病增加
      • 低成本仿製药的供应
      • 老年人口增加
    • 抑制因素
      • 对仿製药品质的担忧
    • 机会
      • 品牌药的专利到期及新产品的核准
  • 新冠肺炎 (COVID-19) 市场影响分析

第 4 章仿製药市场：依治疗用途划分

  • 摘要
  • 心血管
  • 传染病
  • 癌症
  • 糖尿病
  • 其他

第5章仿製药市场：依给药途径

  • 摘要
  • 口服製剂
  • 注射药品
  • 其他

第6章仿製药市场：依通路划分

  • 摘要
  • 医院药房
  • 零售药局
  • 线上提供者

第7章仿製药市场：依地区划分

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他领域

第8章竞争态势

  • 简介
  • 关键成功策略
  • 10家主要公司的产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022 年主要公司的定位

第9章公司简介

  • Amneal Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd
  • Cipla Ltd
  • Hikma Pharmaceuticals PLC
  • Lupin
  • Aurobindo Pharma
Product Code: A03793

According to a new report published by Allied Market Research, titled, "Generic Drugs Market," The generic drugs market was valued at $385.3 billion in 2022, and is estimated to reach $835.7 billion by 2032, growing at a CAGR of 8.1% from 2023 to 2032.

Generic Drugs Market - IMG1

Generic drugs is a medication similar to a branded drug, which has previously been approved for marketing in terms of dose form, potency, mode of administration, quality, performance characteristics, and intended purpose. The generic drugs are available at lower prices as compared to branded drugs.

The growth of the generic drugs market is driven by surge in prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases. According to World Cancer Research Fund International (WCRF), there were an estimated 18.1 million cancer cases globally in 2020, of which 9.3 million cases were in men and 8.8 million in women. In addition, the affordable price of generic drugs and latest product approval and product launch contribute to the growth of the market. For instance, in February 2021, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India.

Moreover, the rise in cost of branded medication, high demand for generic medicines, and rise in awareness about generic drugs contribute to the growth of the market. In addition, prominent players in the global generic drugs market have adopted various strategies such as product launches, acquisition, and investments in R&D for advancement in generic drugs to strengthen their position in the market and sustain the competitive environment.

Moreover, alarming increase in prevalence of diabetes, technological advancements in generic drugs, and rise in the geriatric population are some of the key factors driving the growth of the market. The geriatric population are more prone to chronic diseases such as diabetes and hypertension. However, concern related to the consistency and stability of generic drugs hamper the market growth. Conversely, increase in awareness of generic drugs among the population is expected to provide lucrative opportunities for the growth of the market in the near future. In addition, extensive R&D activities in the field of generic drugs along with significant improvement in medical infrastructure is anticipated to open new avenues for the expansion of the market during the forecast period.

The generic drugs market is segmented into therapeutic application, route of administration, distribution channel, and region. On the basis of therapeutic application, the market is divided into cardiovascular, infectious diseases, cancer, diabetes, and others. Based on the route of administration, the market is classified into oral, injection and others.

Depending on distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online providers. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major companies profiled in the report include: Amneal Pharmaceuticals, Aurobindo Pharma, Cipla, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Sandoz International GmbH, Sun Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the generic drugs market analysis from 2022 to 2032 to identify the prevailing generic drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the generic drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global generic drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online providers

By Therapeutic Application

  • Cardiovascular
  • Infectious Diseases
  • Cancer
  • Diabetes
  • Others

By Route of Administration

  • Oral
  • Injections
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Amneal Pharmaceuticals, Inc.
    • Aurobindo Pharma
    • Cipla Ltd
    • GlaxoSmithKline plc
    • Hikma Pharmaceuticals PLC
    • Lupin
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceutical Industries Limited
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of chronic diseases
      • 3.4.1.2. Availability of low-cost generic drugs
      • 3.4.1.3. Upsurge in geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. Concern related to the quality of generic drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Patent expiry of branded drugs and new product approvals
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Cardiovascular
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Infectious Diseases
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Cancer
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Diabetes
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Injections
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: GENERIC DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Therapeutic Application
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Therapeutic Application
      • 7.2.5.1.3. Market size and forecast, by Route of Administration
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Therapeutic Application
      • 7.2.5.2.3. Market size and forecast, by Route of Administration
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Therapeutic Application
      • 7.2.5.3.3. Market size and forecast, by Route of Administration
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Therapeutic Application
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Therapeutic Application
      • 7.3.5.1.3. Market size and forecast, by Route of Administration
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Therapeutic Application
      • 7.3.5.2.3. Market size and forecast, by Route of Administration
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Therapeutic Application
      • 7.3.5.3.3. Market size and forecast, by Route of Administration
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Therapeutic Application
      • 7.3.5.4.3. Market size and forecast, by Route of Administration
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Therapeutic Application
      • 7.3.5.5.3. Market size and forecast, by Route of Administration
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Therapeutic Application
      • 7.3.5.6.3. Market size and forecast, by Route of Administration
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Therapeutic Application
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Therapeutic Application
      • 7.4.5.1.3. Market size and forecast, by Route of Administration
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Therapeutic Application
      • 7.4.5.2.3. Market size and forecast, by Route of Administration
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Therapeutic Application
      • 7.4.5.3.3. Market size and forecast, by Route of Administration
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Therapeutic Application
      • 7.4.5.4.3. Market size and forecast, by Route of Administration
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Therapeutic Application
      • 7.4.5.5.3. Market size and forecast, by Route of Administration
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Therapeutic Application
      • 7.4.5.6.3. Market size and forecast, by Route of Administration
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Therapeutic Application
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Therapeutic Application
      • 7.5.5.1.3. Market size and forecast, by Route of Administration
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Therapeutic Application
      • 7.5.5.2.3. Market size and forecast, by Route of Administration
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Therapeutic Application
      • 7.5.5.3.3. Market size and forecast, by Route of Administration
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Therapeutic Application
      • 7.5.5.4.3. Market size and forecast, by Route of Administration
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Amneal Pharmaceuticals, Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. GlaxoSmithKline plc
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Novartis AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Teva Pharmaceutical Industries Limited
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Viatris Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Sun Pharmaceutical Industries Ltd
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Cipla Ltd
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Hikma Pharmaceuticals PLC
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Lupin
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Aurobindo Pharma
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 02. GENERIC DRUGS MARKET FOR CARDIOVASCULAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GENERIC DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. GENERIC DRUGS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GENERIC DRUGS MARKET FOR DIABETES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 08. GENERIC DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GENERIC DRUGS MARKET FOR INJECTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 12. GENERIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GENERIC DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GENERIC DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GENERIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 22. U.S. GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. CANADA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 25. CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. UK GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. UK GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 41. UK GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. ITALY GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. ITALY GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 44. ITALY GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 55. CHINA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. CHINA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 57. CHINA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. INDIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. INDIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 63. INDIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 81. SAUDI ARABIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 84. SOUTH AFRICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LAMEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. AMNEAL PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 90. AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 91. AMNEAL PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 92. AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 93. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 94. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 95. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 96. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 97. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 98. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 99. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 100. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 105. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 106. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 107. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 108. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 109. VIATRIS INC.: KEY STRATERGIES
  • TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
  • TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
  • TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
  • TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
  • TABLE 114. CIPLA LTD: KEY EXECUTIVES
  • TABLE 115. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 116. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 117. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 118. HIKMA PHARMACEUTICALS PLC: KEY EXECUTIVES
  • TABLE 119. HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
  • TABLE 120. HIKMA PHARMACEUTICALS PLC: PRODUCT SEGMENTS
  • TABLE 121. HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
  • TABLE 122. LUPIN: KEY EXECUTIVES
  • TABLE 123. LUPIN: COMPANY SNAPSHOT
  • TABLE 124. LUPIN: PRODUCT SEGMENTS
  • TABLE 125. LUPIN: PRODUCT PORTFOLIO
  • TABLE 126. LUPIN: KEY STRATERGIES
  • TABLE 127. AUROBINDO PHARMA: KEY EXECUTIVES
  • TABLE 128. AUROBINDO PHARMA: COMPANY SNAPSHOT
  • TABLE 129. AUROBINDO PHARMA: PRODUCT SEGMENTS
  • TABLE 130. AUROBINDO PHARMA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. GENERIC DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF GENERIC DRUGS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN GENERIC DRUGS MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALGENERIC DRUGS MARKET
  • FIGURE 09. GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR CARDIOVASCULAR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR INJECTIONS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. GENERIC DRUGS MARKET BY REGION, 2022
  • FIGURE 24. U.S. GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. JAPAN GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SAUDI ARABIA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. SOUTH AFRICA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LAMEA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: GENERIC DRUGS MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2022
  • FIGURE 50. AMNEAL PHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. AMNEAL PHARMACEUTICALS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. SUN PHARMACEUTICAL INDUSTRIES LTD: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. HIKMA PHARMACEUTICALS PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. HIKMA PHARMACEUTICALS PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. HIKMA PHARMACEUTICALS PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 70. LUPIN: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. AUROBINDO PHARMA: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. AUROBINDO PHARMA: REVENUE SHARE BY REGION, 2021 (%)